Prophase Labs, Inc. (PRPH) Stock Price & Analysis
Prophase Labs, Inc. (PRPH) rose 0.00% to USD 0.1 as of June 10, 2026 at 08:34 UTC, according to Nexqual real-time market data.
PRPH last closed at USD 0.1; the session ranged USD 0.1–0.1 on volume of 853 shares. Market capitalization is $1.40M, with a 52-week range of USD 0.07–6.7 (PNK). Source: Nexqual, June 10, 2026 at 08:34 UTC.
Key Statistics (as of June 10, 2026 at 08:34 UTC)
| Price | USD 0.1 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.1 |
| Open | USD 0.1 |
| Day Range | USD 0.1 – 0.1 |
| 52-Week Range | USD 0.07 – 6.7 |
| Volume | 853 shares |
| Market Cap | $1.40M |
| Exchange | PNK |
Technical Analysis (PRPH)
Nexqual's technical model rates PRPH "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.09 (neutral) |
| vs SMA50 | Below (USD 0.11) |
| MACD | -0 (negative) |
Analyst Ratings (PRPH)
Wall Street analysts rate PRPH "None", per Nexqual as of June 10, 2026 at 08:34 UTC.
| Consensus Rating | None |
|---|
Earnings (PRPH)
| Next Earnings Date | 2026-06-09 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-06-30 | USD -0.81 vs est -1.5 ▲ beat |
| 2025-03-31 | USD -1.21 vs est -1.8 ▲ beat |
| 2024-12-31 | USD -15.9 vs est -2.4 ▼ miss |
| 2024-09-30 | USD -3.5 vs est -3.1 ▼ miss |
Source: Nexqual, June 10, 2026 at 08:34 UTC.
Financials & Fundamentals (PRPH)
| Total Revenue | $4.34M |
|---|---|
| Revenue Growth (YoY) | -47.50% |
| Gross Margin | +31.85% |
| Operating Margin | -730.36% |
| Profit Margin | +0.00% |
| ROE | -430.66% |
| Debt / Equity | 245.67 |
| Current Ratio | 0.06 |
| Total Cash | $90,000 |
| Total Debt | $8.62M |
| Free Cash Flow | $43.01M |
Source: Nexqual, June 10, 2026 at 08:34 UTC.
Financial Health Score (PRPH)
Nexqual rates Prophase Labs, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:34 UTC.
| Growth | Critical — Revenue -85% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $90K cash vs $9M debt |
| Cash Flow | Strong — FCF $43M, 633% margin |
| Efficiency | Critical — ROE -431%, ROA -18.3% |
Ownership (PRPH)
| Insider Ownership | +2.37% |
|---|---|
| Institutional Ownership | +0.07% |
| Shares Outstanding | 14.02M |
| Float | 13.68M |
| Short % of Float | +0.71% |
Source: Nexqual, June 10, 2026 at 08:34 UTC.
Leadership (PRPH)
Prophase Labs, Inc. is led by Ted William Karkus (age 66), Chairman & CEO, per Nexqual as of June 10, 2026 at 08:34 UTC.
| Chairman & CEO | Ted William Karkus (age 66) |
|---|---|
| President of Nebula Genomics | Jason Karkus |
| Chief Product Officer of Nebula Genomics | Kevin Quinn |
Major Backers & Investors (PRPH)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.2% |
Source: Nexqual, June 10, 2026 at 08:34 UTC.
From Prophase Labs, Inc.'s Latest SEC 10-K Filing (filed 2026-06-01)
Key Strengths & Strategy (as disclosed to the SEC)
- ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.
- It operates through two segments: Diagnostic Services and Consumer Products.
- The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster.
- In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CPIX | Cumberland Pharmaceuticals Inc. | USD 5.72 | ▼ 1.38% |
| NAII | Natural Alternatives Internatio | USD 2.51 | ▲ 0.2% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
| XTLB | XTL Biopharmaceuticals Ltd. | USD 2.32 | ▲ 12.62% |
| ICCC | ImmuCell Corporation | USD 9.77 | ▲ 1.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:34 UTC. This page is informational and not investment advice.